Skip to main content
. 2018 May 29;9(41):26431–26452. doi: 10.18632/oncotarget.25449

Figure 5. Cross-validation of parenchymal CD44 and CDH17 expression and stromal PD-L2 and ORL-1 expression in tumor xenograft tissue.

Figure 5

(A) Parenchymal CD44 immunostaining. (B) Parenchymal CDH17 immunostaining. (C) Stromal PD-L2 immunostaining. (D) Stromal LOX-1 immunostaining. Bar = 100 μm.